Jin Zhixian, Pan Xinghua, Zhou Kaihua, Bi Hong, Wang Liyan, Yu Lu, Wang Qing
Second Department of Respiratory Medicine, The First People's Hospital of Kunming, Kunming, Yunnan Province, China.
Stem Cell Engineering Laboratory of Yunnan Province, Department of Clinical Research, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan Province, China.
J Int Med Res. 2015 Jun;43(3):303-10. doi: 10.1177/0300060514568733. Epub 2015 Apr 1.
Chronic obstructive pulmonary disease (COPD) is the most frequent chronic respiratory disease and a leading cause of morbidity and mortality, worldwide. Given that the foremost risk factor leading to the development of COPD is cigarette smoke, the initial treatment for COPD is smoking cessation. Even after smoking cessation, inflammation, apoptosis and oxidative stress can persist and continue to contribute to COPD. Although current therapies for COPD (which are primarily based on anti-inflammatory drugs such as corticosteroids, theophylline and bronchodilators) reduce airway obstruction, limit COPD exacerbation and improve the patient's health-related quality-of-life, none can prevent disease progression or reduce mortality. Recent advances in stem cell research have provided novel insight into the potential of bone marrow mesenchymal stem cells (MSCs) in the treatment of several pulmonary diseases. This review article discusses the biological effects and mechanisms of action of MSC transplantation in COPD, and highlights the foundation that MSCs provide for novel therapeutic approaches in COPD.
慢性阻塞性肺疾病（COPD）是全球最常见的慢性呼吸道疾病，也是发病和死亡的主要原因。鉴于导致COPD发生的首要危险因素是香烟烟雾，COPD的初始治疗方法是戒烟。即使戒烟后，炎症、细胞凋亡和氧化应激仍会持续存在，并继续促使COPD的发展。尽管目前治疗COPD的方法（主要基于抗炎药物，如皮质类固醇、茶碱和支气管扩张剂）可减轻气道阻塞、限制COPD急性加重并改善患者的健康相关生活质量，但没有一种方法能够阻止疾病进展或降低死亡率。干细胞研究的最新进展为骨髓间充质干细胞（MSCs）治疗多种肺部疾病的潜力提供了新的见解。这篇综述文章讨论了MSCs移植在COPD中的生物学效应和作用机制，并强调了MSCs为COPD新型治疗方法奠定的基础。
